资源描述
2009 1210 2024 01 11 NPH 2022 58%2022 47%U100 Lantus 69 26 Lantus Toujeo 10 365 52 GLP-1 STAY GLP-1 6 12 GLP-1 23%35%Icodec NDA Efsitora alfa LY-3209590 III GZR4 II Icodec Icodec 2020 12 Icodec IIIa ONWARDS ONWARDS Icodec Icodec IcoSema 2023 4 Icodec 2024 Icodec Icodec Efsitora alfa Icodec 2024 GLP-1 1 2 3 S0360520110002%()476 0.06()66,819.10 7.92()54,074.81 8.27%1M 6M 12M-7.1%-5.7%-14.1%-3.5%9.1%3.7%20240107 BI NASH 2024-01-08 23 3 2024-01-07&59 RDN 2024-01-06-18%-11%-3%5%23/01 23/03 23/06 23/08 23/10 24/012023-01-112024-01-11 300 2009 1210.5.5.7.9.10.10.11.12 Icodec.13.13 ONW ARDS Icodec.14 IcoSema.16 Icodec.17.19.19 1.19 2.20.20 GLP-1.21.23.25 XVEVyRrMmPrQrPoNsPtMpO8O9R8OoMmMnPrNeRrRqRjMoPsQ7NpPwOMYpMxPwMmNnQ 2009 1210 3 1.5 2.5 3.5 4.7 5.7 6.7 7.8 8.9 9.9 10.9 11.9 12 Lantus.10 13 Toujeo.10 14.10 15.10 16.11 17.11 18 GLP-1.12 19.12 20.12 21 Icodec.13 22.14 23 Icodec ONWARDS.15 24 ONWARDS.16 25.16 26.17 27.17 28 IcoSema.17 29 Icodec.18 30.19 31 EGFR-TKI.19 32.20 33.21 2009 1210 4 34 2022.21 35 GLP-1.22 36 GLP-1.23 37.23 38.24 2009 1210 5 Insulin Human A 11 21 B 15 30 50%1 2 healthjade ALLISON PETZNICK,DO.Insulin Management of Type 2 Diabetes Mellitus 1921 100/3 RI 15-60min 2-4h 5-8h 10-15min 1-2h 4-6h 10-15min 1-1.5h 4-5h 2009 1210 6 10-15min 1-2h 4-6h NPH 2.5-3h 5-7h 13-16h PZI 3-4h 8-10h 20h 3-4h 16-24h U100 2-3h 30h 1h 42h U300 6h 36h 30R 70/30 0.5h 2-12h 14-24h 40R 60/40 0.5h 2-8h 24h 50R 50/50 0.5h 2-3h 10-24h 30 10-20min 1-4h 14-24h 50 15min 30-70min 16-24h 25 15min 30-70min 16-24h 50 15min 30-70min 16-24h 10-15min 1.2h 24h 2 2 2020 2022 American Diabetes Association ADA HbA1c+1-3/2-3 2 1-3+2-3 2 2020 GLP-1 1-2/GLP-1 2009 1210 7 4 5 2 2020 1 2 2 2020 neutral protamine Hagedorn insulin NPH NPH 24 6 2023 IDF U100 U300 2009 1210 8 U100 A 21 B 30 B31 B32 2 pH U100 12 30 U300 U100 U300 19 36 U100 U300 7 Kitty Poon et al.Glargine and detemir:Safety and efficacy profiles of the long-acting basal insulin analogs B 30 B 29 14 24 NPH U100 B 30 B 29 16 25.4 42 U100 2009 1210 9 8 9 Kitty Poon et al.Glargine and detemir:Safety and efficacy profiles of the long-acting basal insulin analogs Scott R.Drab et al.A New Option for Glycemic Control:Insulin Degludec,a New-Generation Basal Insulin with an Ultralong Duration of Action Bloomberg 2022 291.6 58%2022 150.3 28.1%47%10 11 Bloomberg 2000 Lantus FDA 2015 Lantus 69 2015 Lantus U300 Toujeo 2022 Toujeo 12.1 15.3%2009 1210 10 12 Lantus 13 Toujeo 1=1.08 1=1.08 2005 Levemir 26.4 2015 2022 14.0-4%14 15 1 2 3/U300 2 2 3 HbA1c 7.0%2009 1210 11 HbA1c 8.9%HbA1c 10%7%HbA1c D dac Mauricio et al.Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA 3 24 HbA1c 7.0%8.1%-28.0%17.3%-33.4%16 17 Vincent Woo 2023-2 IDF D dac Mauricio et al.Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA U300 1 2-4 365 52 GLP-1 STAY 1 GLP-1 6 12 GLP-1 23%35%GLP-1 34 2017 12 FDA 90 1 William H.Polonsky.Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice STAY Study 2009 1210 12 18 GLP-1 19 William H.Polonsky.Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice STAY Study Hanmi I Icodec NDA Efsitora alfa LY-3209590 III GZR4 II 20/Icodec+NDA Efsitora alfa Fc III GZR4 II HM12470 Fc Hanmi I HM12460A Fc Hanmi I AKS-440 Fc Akston Biosciences SC-Insulin-Fc Fc PE0139 ELP PhaseBio AB101 PEG Rezolute GZR4 Icodec Icodec Icodec A14 B16 B25 2009 1210 13 ONW ARDS IIIa 2023 4 Icodec 2024 21 Icodec 2023 IDF Fc Fc Efsitora alfa LY-3209590 IgG Fc LY-3209590 17 LY-3209590 III 2021 LY3209590 2 II 32 LY3209590 HbA1c LY3209590 Icodec-Icodec B30 20-L-B29 Icodec 9.5 2009 1210 14 22 A B B30 B29 14 5-7h 16-24h B30 L-1 16 B29 24h 42h Icodec A14 B30-L-1 20 B29 B16 B25 196h 168h Icodec Icodec 20 Icodec 3 A14 B16 B25 Icodec insulin receptor IR Icodec IR 5.5%2 20 IR Icodec 1.5%HSA Icodec 5.5%0.03%Icodec Icodec A14E A14 B25H B25 Icodec 700U/mL 100U/mL 7 Icodec 3 ONW ARDS Icodec 2020 12 Icodec IIIa ONW ARDS ONW ARDS 6 ONWARDS 1-6 4347 1 2 Icodec 2022 2023 4 ONW ARDS IIIa Icodec 2024 2 Erica Nishimura et al.Molecular and pharmacological characterization of insulin icodec:a new basal insulin analog designed for once weekly dosin 3.Icodec 2009 1210 15 23 Icodec ONWARDS ONWARDS 1 ONWARDS 2 ONWARDS 3 ONWARDS 4 ONWARDS 5 ONWARDS 6 984 526 588 582 1085 582 T2D T2D T2D T2D T2D T1D 52 26 26 26 52 26 U100 app 52 HbA1c 26 HbA1c 26 HbA1c 26 HbA1c 52 HbA1c 26 HbA1c 2023 ONW ARDS ONW ARDS 2 2 1 ONW ARDS U100 U100 U300 Icodec 1 ONW ARDS 1 3 5 Icodec 2 HbA1c U100-1.55%vs-1.35%-1.57%vs-1.36%U100 U300-1.68%vs-1.31%Icodec Icodec Icodec 2 ONW ARDS 2 4 2 Icodec-0.93%vs-0.71%U100-1.16%vs-1.18%Icodec Icodec Icodec 3 ONW ARDS 6 Icodec 1 HbA1c-0.47%vs-0.51%Icodec ONW ARDS Icodec Icodec 2009 1210 16 24 ONWARDS 2023 IcoSema 2015 FDA 2016/25 2015 2017/Ryzodeg 2016 2021/Xultophy 2016 2021 2017 2021/Cagrisema III III/Icosema III III Tresiba/Ryzodeg/Xultophy/2022 14.0-4%17-22 CAGR=5%Ryzodeg 2022 4.3+69%17-22 CAGR=42%Xultophy 2022 4.2+6%17-22 CAGR=31%2009 1210 17 26 27/Icodec IcoSema GLP-1 2021Q4 IcoSema III COMBINE COMBINE 3 COMBINE 1-3 2024 COMBINE 3 COMBINE 3 52 2 1 IcoSema 1 2-4 COMBINE 3 IcoSema+28 IcoSema 2023 Icodec Icodec 2009 1210 18 Icodec Icodec Icodec Icodec IcoSema Icodec Icodec 12.8 92 Icodec 29 Icodec Wind IDF 10 2(2022)CDC National Diabetes Statistics Report American Diabetes Association HCCI International Health Cost Comparison Report 2022 countrymeters IDF 2017 mordorintelligence Europe Insulin Drugs Market Size and Share Analysis-Growth Trends and Forecasts 2023-2028 2009 1210 19 Icodec Efsitora alfa Icodec 2024 GLP-1 EGFR-TKI 2002 2022 20%2017 2022 7%EGFR-TKI 1%77%EGFR-TKI 2022 99%19%30 31 EGFR-TKI/GLP-1 1 4mm 32G 5mm 31G 6mm 31G 2009 1210 20 2 2009 2017 2023 I II 2023 32 2009 2017 2017 2009 I 2017 I II 2023 2017 I II 2023 2009 2017 I II 2023 2019 II 2023 Icodec Efsitora alfa GZR4 GZR4 2022 7 7 NMPA 2022 9 I 2023 9 2022 8 GZR4 FDA IND I 2009 1210 21 33 Icodec INS068 III III Efsitora alfa III III GZR4 I II GZR33 I I-I GLP-1 GLP-1 II GLP-1 GLP-1 GLP-1 2022 4 GLP-1 2017 12 2022 86+66%GLP-1 NASH 34 2022 1 GLP-1 2 GLP-1 GLP-1 2023 12 THDBH120 THDBH110 GLP-1 GLP-1 GZR18 II II I GLP-1 GLP-1 GLP-1 GLP-1 1 2023 12 NMPA II 2009 1210 22 2 THDBH120 THDBH120 GLP1R/GIPR THDBH120 2023 12 Ia NASH 3 THDBH110 THDBH110 GLP-1 THDBH110 2023 12 THDBH110 II I 35 GLP-1 GLP1R II 2023/11/28 THDBH120 GLP1R/GIPR II I 2023/11/14 THDBH110 GLP1R II I 2023/12/05 GZR18 GLP-1 GZR18 GZR18 GLP-1 GLP-1 94%2022 6 GZR18 European Journal of Pharmacology GZR18 2023 6 GZR18/IIb 7 GZR18 IIb GLP-1 2023 12 GZR18 GZR18 2 NMPA 2022 3 GZR18 I IcoSema GLP-1/GZR4 GZR18 GLP-1 GLP-1/2009 1210 23 36 GLP-1 GZR18 GLP1R II IIb 2023/7/10 II I 2022/3/11/IIb 2023/6/12 II 2023/12/1 2003 2013 2023 1 2024 2023 9 FDA 2020 FDA NDA BLA BLA CMC+I PK/PD 2005 2023H1 19 51 18 2013 2018 12 18 Sandoz Sandoz 2023 2 FDA 2023 6 FDA BLA 2023 8 10 EMA 2024 FDA FDA EMA 37 Lantus 2000/4/20 Toujeo 2015/2/25 Basaglar 2015/12/16 Mylan/Biocon Semglee 2020/6/11 2021/7/28 Rezvoglar 2021/12/17 2022/11/16 2009 1210 24/Sandoz-2023/2/24/Lannett-BLA-/-BLA-NovoLog 2000/6/7 NovoLog Mix 2001/11/1 Fiasp 2017/9/29/Sandoz-2023/6/14 Truvelog Mix III 2020/7/8 Amphastar Pharmaceuticals-II/III 2023/1/30 Mylan/Biocon Kixelle III 2020/1/17 Lannett-BLA-24 BLA 25/-BLA-Humalog 1996/6/14 Humalog Mix 1999/12/22 Lyumjev 2020/6/15 Admelog 2017/12/11/Sandoz-2023/6/1/-BLA-38 Lantus 2000/6/9 Toujeo 2015/4/28 Basaglar 2014/9/9 Biocon Semglee 2018/3/23/Sandoz-2023/8/22 NovoRapid 1999/9/7 Novo Mix 2000/8/1 Fiasp 2017/1/9 Truvelog 2020/6/25 Biocon Kirsty 2021/2/5 Truvelog Mix 30 2022/4/25-2023/10/9 Geropharm GP40081 III 2020/12/25 III Humalog 1996/4/30 Liprolog 2001/8/1 Liprolog 2023 5 Lyumjev 2020/3/24 2009 1210 25 Admelog 2017/7/18-2023/10/9 1 2 3 2009 1210 26 2020 2020 2020 2020 2020 2020 2020 2023 2021 2022 2022 2022 2023 2023 2009 1210 27 010-63214682 010-63214682 010-63214682 010-63214682 010-63214682 010-66500808 010-66500821 010-63214682 0755-82828570 0755-83715428 0755-82756804 0755-82871425 0755-82871425 021-20572536 021-20572555 021-20572257-2552 021-20572506 021-20572585 021-20572509 021-20572548 021-20572573 0755-82756805 021-20572559 021-20572559 0755-82756805 021-20572559 玙 021-25072549 2009 1210 28 A 300 500/6 20%6 10%20%6-10%10%6 10%20%3-6 5%3-6-5%5%3-6 5%26 C 3A 1061 A 19 33 12 100033 518034 200120 010-66500801 0755-82027731 021-20572500 010-66500900 0755-82828562 021-20572522
展开阅读全文